{
    "organizations": [],
    "uuid": "ec4e36fde88cd0e65beb58c358b57fa2bb276d0a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-proqr-and-galapagos-announce-resea/brief-proqr-and-galapagos-announce-research-collaboration-idUSFWN1P30JM",
    "ord_in_thread": 0,
    "title": "BRIEF-ProQR And Galapagos Announce Research Collaboration",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Galapagos Nv:\n* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY\n* PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS\n* PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T20:13:00.000+02:00",
    "crawled": "2018-01-09T17:17:25.021+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "galapagos",
        "nv",
        "proqr",
        "galapagos",
        "announce",
        "research",
        "collaboration",
        "fibrosis",
        "target",
        "using",
        "proqr",
        "technology",
        "proqr",
        "therapeutic",
        "agreement",
        "two",
        "company",
        "work",
        "together",
        "discover",
        "novel",
        "axiomer",
        "eon",
        "fibrosis",
        "target",
        "selected",
        "galapagos",
        "proqr",
        "therapeutic",
        "target",
        "pursued",
        "collaboration",
        "financial",
        "detail",
        "collaboration",
        "disclosed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}